Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Hutchison MediPharma Out-licenses Cancer Drug to Lilly for $86.5 Million

publication date: Oct 10, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Hutchison MediPharma, which is majority owned by Chi-Med, announced it would partner its cancer drug fruquintinib (HMPL-013) with Lilly. Lilly will make up to $86.5 million in upfront and milestone payments to HMP in return for China rights to fruquintinib. The drug, which is in a Phase II clinical trial, is a selective inhibitor of the Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinases. HMP believes it will be an effective treatment for several solid tumor cancers. More details....

Stock Symbols: (AIM: HCM) (NYSE: LLY)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners